Demographic, regional and temporal trends of hyperuricemia epidemics in mainland China from 2000 to 2019: a systematic review and meta-analysis
Background Hyperuricemia (HUA) is becoming a global public health problem and associated with multiple diseases. Objective We conducted a systematic review to synthesize the pooled prevalence of HUA in mainland China and delineate its demographic, regional, and temporal trends over the past two decades. Methods Systematic literature searches of PubMed, SCOPUS, Web of Science, the China National Knowledge Infrastructure (CNKI), and the Wanfang digital database were conducted to screen studies published from 1 January 2000 to 31 August 2019, reporting the prevalence of HUA in mainland China. The search strings were (‘hyperuricemia’ OR ‘hyperuricaemia’ OR ‘uric acid’) AND (‘prevalence’ OR ‘epidemiology’) AND ‘China’. Article quality was appraised quantitatively from 11 items. Before formal meta-analysis, age-standardized prevalence was transformed. The random-effects model was applied to synthesize the pooled prevalence due to its high heterogeneity. Then we stratified the prevalence estimates by age, gender, area, nationality, and publication year for subgroup analysis. Results Totally 177 eligible studies with a whole population of 2,277,712 were included in the present meta-analysis. The pooled prevalence in mainland China was estimated at 16.4% (95% CI: 15.3%~17.6%). In studies with the onset age at 20 ~ 29 years old, males had a twice times higher HUA prevalence than females (21.5% vs. 8.9%). The prevalence of HUA was 13.7% (11.8%~15.7%) in people aged 15~ years old, 16.5% in 30~ (14.8%~18.4%), 17.9% in 40~ (16.4%~19.5%), 19.4% in 50~ (17.8%~21.0%), 20.5% in 60~ (18.8%~22.3%), and 24.9% in over 70 (22.9%~27.1%). Stratified by regions, southern (25.5%) and southwestern (21.2%) China shared the highest prevalence, and the lowest prevalence was observed in the northwest (12.6%). From 2001 to 2017, the prevalence estimates of HUA steadily climbed from 8.5% to 18.4% with minor fluctuations. Multiple regression revealed that HUA prevalence was positively correlated to the larger sample size, area, advanced onset age, and published year. Conclusions The last two decades witnessed the rapid growth prevalence of HUA in China. Early screening and personalized health education for HUA need to be given enough attention..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Global Health Action - 14(2021), 1 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang Li [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
China |
|---|
| doi: |
10.1080/16549716.2021.1874652 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ064307417 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ064307417 | ||
| 003 | DE-627 | ||
| 005 | 20230309035305.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/16549716.2021.1874652 |2 doi | |
| 035 | |a (DE-627)DOAJ064307417 | ||
| 035 | |a (DE-599)DOAJ71710ac303894c298e2d7bccfabe8eae | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RA1-1270 | |
| 100 | 0 | |a Yang Li |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Demographic, regional and temporal trends of hyperuricemia epidemics in mainland China from 2000 to 2019: a systematic review and meta-analysis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background Hyperuricemia (HUA) is becoming a global public health problem and associated with multiple diseases. Objective We conducted a systematic review to synthesize the pooled prevalence of HUA in mainland China and delineate its demographic, regional, and temporal trends over the past two decades. Methods Systematic literature searches of PubMed, SCOPUS, Web of Science, the China National Knowledge Infrastructure (CNKI), and the Wanfang digital database were conducted to screen studies published from 1 January 2000 to 31 August 2019, reporting the prevalence of HUA in mainland China. The search strings were (‘hyperuricemia’ OR ‘hyperuricaemia’ OR ‘uric acid’) AND (‘prevalence’ OR ‘epidemiology’) AND ‘China’. Article quality was appraised quantitatively from 11 items. Before formal meta-analysis, age-standardized prevalence was transformed. The random-effects model was applied to synthesize the pooled prevalence due to its high heterogeneity. Then we stratified the prevalence estimates by age, gender, area, nationality, and publication year for subgroup analysis. Results Totally 177 eligible studies with a whole population of 2,277,712 were included in the present meta-analysis. The pooled prevalence in mainland China was estimated at 16.4% (95% CI: 15.3%~17.6%). In studies with the onset age at 20 ~ 29 years old, males had a twice times higher HUA prevalence than females (21.5% vs. 8.9%). The prevalence of HUA was 13.7% (11.8%~15.7%) in people aged 15~ years old, 16.5% in 30~ (14.8%~18.4%), 17.9% in 40~ (16.4%~19.5%), 19.4% in 50~ (17.8%~21.0%), 20.5% in 60~ (18.8%~22.3%), and 24.9% in over 70 (22.9%~27.1%). Stratified by regions, southern (25.5%) and southwestern (21.2%) China shared the highest prevalence, and the lowest prevalence was observed in the northwest (12.6%). From 2001 to 2017, the prevalence estimates of HUA steadily climbed from 8.5% to 18.4% with minor fluctuations. Multiple regression revealed that HUA prevalence was positively correlated to the larger sample size, area, advanced onset age, and published year. Conclusions The last two decades witnessed the rapid growth prevalence of HUA in China. Early screening and personalized health education for HUA need to be given enough attention. | ||
| 650 | 4 | |a hyperuricemia | |
| 650 | 4 | |a china | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a systematic review | |
| 650 | 4 | |a meta-analysis | |
| 653 | 0 | |a Public aspects of medicine | |
| 700 | 0 | |a Ziyan Shen |e verfasserin |4 aut | |
| 700 | 0 | |a Bowen Zhu |e verfasserin |4 aut | |
| 700 | 0 | |a Han Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Xiaoyan Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Xiaoqiang Ding |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Global Health Action |d Taylor & Francis Group, 2008 |g 14(2021), 1 |w (DE-627)DOAJ00009269X |x 16549880 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2021 |g number:1 |
| 856 | 4 | 0 | |u https://doi.org/10.1080/16549716.2021.1874652 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/71710ac303894c298e2d7bccfabe8eae |z kostenfrei |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/16549716.2021.1874652 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1654-9880 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2021 |e 1 | ||